Cargando…
S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428475/ http://dx.doi.org/10.1097/01.HS9.0000967776.81028.41 |
| _version_ | 1785090478841004032 |
|---|---|
| author | Zhang, Huilai Yu, Jingwei LI, He Qian, Wenbin Xiao, Xibin Cai, Qingqing Liu, Yao Zhang, Yu Zhang, Liling Qin, Ling Zhou, Hui Tang, Xiaoyi Guo, Yingmei Zhou, Hui Niu, Ting |
| author_facet | Zhang, Huilai Yu, Jingwei LI, He Qian, Wenbin Xiao, Xibin Cai, Qingqing Liu, Yao Zhang, Yu Zhang, Liling Qin, Ling Zhou, Hui Tang, Xiaoyi Guo, Yingmei Zhou, Hui Niu, Ting |
| author_sort | Zhang, Huilai |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428475 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284752023-08-17 S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY Zhang, Huilai Yu, Jingwei LI, He Qian, Wenbin Xiao, Xibin Cai, Qingqing Liu, Yao Zhang, Yu Zhang, Liling Qin, Ling Zhou, Hui Tang, Xiaoyi Guo, Yingmei Zhou, Hui Niu, Ting Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428475/ http://dx.doi.org/10.1097/01.HS9.0000967776.81028.41 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Zhang, Huilai Yu, Jingwei LI, He Qian, Wenbin Xiao, Xibin Cai, Qingqing Liu, Yao Zhang, Yu Zhang, Liling Qin, Ling Zhou, Hui Tang, Xiaoyi Guo, Yingmei Zhou, Hui Niu, Ting S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title | S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title_full | S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title_fullStr | S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title_full_unstemmed | S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title_short | S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title_sort | s216: cd47/pd-l1 bispecific antibody (ibi322) in anti-pd-1 or pd-l1 treatment-resistant classical hodgkin lymphoma: a phase i study |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428475/ http://dx.doi.org/10.1097/01.HS9.0000967776.81028.41 |
| work_keys_str_mv | AT zhanghuilai s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT yujingwei s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT lihe s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT qianwenbin s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT xiaoxibin s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT caiqingqing s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT liuyao s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT zhangyu s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT zhangliling s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT qinling s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT zhouhui s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT tangxiaoyi s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT guoyingmei s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT zhouhui s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT niuting s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy |